ArticleAmerican journal of men's health2018
Testosterone Deficiency and Bone Metabolism Damage in Testicular Cancer Survivors.
Article in American journal of men's health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Long-term toxicity of cisplatin in germ-cell tumor survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Pooled it
- Prevalence and predictors of bone density loss in men with low testosterone.The journal of sexual medicine · 2026Article
- Review
- Late side effects of testicular cancer and treatment: a comprehensive review.Discover oncology · 2024Review
- Testicular Cancer Treatments and Sexuality: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Biomarkers to Be Used for Decision of Treatment of Hypogonadal Men with or without Insulin Resistance.Metabolites · 2023Review
- Risk of osteoporosis in testicular germ cell tumour survivors: A systematic review of the literature.BJUI compass · 2023Review
- On the Need to Distinguish between Insulin-Normal and Insulin-Resistant Patients in Testosterone Therapy.International journal of molecular sciences · 2022Review
- Biological Deciphering of the "Kidney Governing Bones" Theory in Traditional Chinese Medicine.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Observational
- Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report.Frontiers in oncology · 2020Article
- Germ Cell NeoplasiaFrontiers in endocrinology · 2019Article
- Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review.Frontiers in endocrinology · 2019Article
- Metabolic patterns in insulin-resistant male hypogonadism.Cell death & disease · 2018Article
- Metabolic patterns in insulin-sensitive male hypogonadism.Cell death & disease · 2018Article
- Increased risk of testis failure in testicular germ cell tumor survivors undergoing radiotherapy.Oncotarget · 2018Article
- Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health.International journal of endocrinology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to investigate the influence of therapeutic modalities and sexual hormone levels on changes in bone mineral density (BMD) in testicular cancer (TC) survivors. In a cross-sectional descriptive, long-term follow-up study, a total of 1,249 long-term TC survivors were evaluated according to treatment modality: orchiectomy (OE) only, OE + chemotherapy (CT), or OE + radiotherapy (RT). Luteinizing hormone (LH), total testosterone (TST), marker of bone resorption (β-carboxyl-terminal cross-linking telopeptide of type I collagen-CTx), and BMD were evaluated. Standard statistical techniques were used to test the differences between groups of patients. TST decrease was observed in 46/313 TC survivors after OE alone, in 103/665 after OE + CT, and in 66/271 after OE + RT. LH increase was observed in 23/313 TC survivors after OE alone, in 154/665 after OE + CT, and in 43/271 after OE + RT. CTx increase was observed in 116/313 TC survivors after OE alone, in 324/665 after OE + CT, and in 82/271 after OE + RT. Osteopenia/osteoporosis occurred in 136/313 TC survivors after OE alone, in 298/665 after OE + CT, and in 139/271 after OE + RT. TC survivors after RT have statistically significant decreased TST levels, increased LH and nonsignificant worse BMD (osteopenia/osteoporosis) in comparison with TC survivors after OE alone or CT. TST decrease and LH increase were statistically significant, more frequently observed in patients with osteopenia/osteoporosis. Examination of TST is an important part of follow-up in TC survivors with bilateral as well as unilateral disease. The important part of standard examination algorithm should be also the osteological examination of TC survivors mainly in patients with androgen deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.